243 related articles for article (PubMed ID: 18184439)
1. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
Wu Y; Mohamed H; Chillar R; Ali I; Clayton S; Slamon D; Vadgama JV
Breast Cancer Res; 2008; 10(1):R3. PubMed ID: 18184439
[TBL] [Abstract][Full Text] [Related]
2. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
Wu Y; Sarkissyan M; Elshimali Y; Vadgama JV
PLoS One; 2013; 8(10):e78259. PubMed ID: 24167614
[TBL] [Abstract][Full Text] [Related]
3. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.
Choi YH; Ahn JH; Kim SB; Jung KH; Gong GY; Kim MJ; Son BH; Ahn SH; Kim WK
Ann Oncol; 2009 Aug; 20(8):1337-43. PubMed ID: 19221151
[TBL] [Abstract][Full Text] [Related]
4. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.
Schmitz KJ; Otterbach F; Callies R; Levkau B; Hölscher M; Hoffmann O; Grabellus F; Kimmig R; Schmid KW; Baba HA
Mod Pathol; 2004 Jan; 17(1):15-21. PubMed ID: 14631376
[TBL] [Abstract][Full Text] [Related]
8. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
Tokunaga E; Kimura Y; Oki E; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Ikebe M; Kakeji Y; Baba H; Maehara Y
Int J Cancer; 2006 Jan; 118(2):284-9. PubMed ID: 16049961
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
10. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
[TBL] [Abstract][Full Text] [Related]
11. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERβ and HER-2 expression.
Wang X; Yi L; Zhu Y; Zou J; Hong Y; Zheng W
Tumori; 2011; 97(2):185-90. PubMed ID: 21617713
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of pAKT and CD44v6 overexpression with breast cancer.
Yu P; Zhou L; Ke W; Li K
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1283-92. PubMed ID: 20157733
[TBL] [Abstract][Full Text] [Related]
13. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
14. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
15. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
16. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Grell P; Fabian P; Khoylou M; Radova L; Slaby O; Hrstka R; Vyzula R; Hajduch M; Svoboda M
Int J Oncol; 2012 Oct; 41(4):1204-12. PubMed ID: 22842582
[TBL] [Abstract][Full Text] [Related]
17. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
Andre F; Nahta R; Conforti R; Boulet T; Aziz M; Yuan LX; Meslin F; Spielmann M; Tomasic G; Pusztai L; Hortobagyi GN; Michiels S; Delaloge S; Esteva FJ
Ann Oncol; 2008 Feb; 19(2):315-20. PubMed ID: 17804473
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hashizume K; Ono M; Kouno T; Ando M; Tamura K; Katsumata N; Hasegawa T; Kinoshita T; Fujiwara Y
Med Oncol; 2009; 26(3):344-9. PubMed ID: 19016009
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Huang L; Chen T; Chen C; Chen S; Liu Y; Wu J; Shao Z
World J Surg Oncol; 2013 Nov; 11():307. PubMed ID: 24289519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
